Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#3798 Intra-arterial PRRT – A prospective clinical study in NET patients with hepatic metastases

Introduction: Liver metastases of neuro-endocrine tumors have a significant impact on survival of patients treated with 177Lu-DOTATATE.

Conference:

Presenting Author:

Authors: Ebbers S, Barentsz M, de Vries-Huizing D, Versleijen M, Klompenhouwer L,

Keywords: PRRT, intra-arterial, lutetium, neuroendocrine tumor, peptide receptor radionuclide therapy, treatment response,

#3535 A case series and literature review of DIPNECH

Introduction: DIPNECH is characterised by bilateral carcinoids ≤0.5cm, tumorlets

Conference:

Presenting Author:

Authors: Montebello A, Ricketts W, Druce M,

Keywords: DIPNECH, clinical presentation, diagnosis, longitudinal behaviour,

#2734 Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review

Introduction: Therapy-related myeloid neoplasm (t-MN) has been reported as a potential long-term and frequently lethal adverse event after PRRT in NET. However, the incidence, time of diagnosis, and nature of t-MN is unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sonbol M

Authors: Sonbol M, Hilal T, Halfdanarson T,

Keywords: PRRT, t-MN, therapy-related myeloid neoplasm, leukemia, NET, MDS,

#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,

Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,